{"id":"gik-and-intensive-insulin-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyperglycemia rebound"},{"rate":null,"effect":"Phlebitis at infusion site"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GIK therapy delivers a high-concentration glucose-insulin-potassium solution to shift myocardial metabolism toward glucose oxidation, which is more efficient under ischemic conditions than fatty acid oxidation. Intensive insulin therapy further optimizes glucose homeostasis and reduces inflammatory markers associated with acute coronary events. Together, these interventions aim to preserve cardiac function and reduce infarct size during acute myocardial infarction.","oneSentence":"GIK (glucose-insulin-potassium) therapy combined with intensive insulin regimens improves myocardial metabolism and reduces ischemic injury by enhancing glucose uptake and oxidative metabolism in cardiac tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:01.897Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction with intensive glycemic control"}]},"trialDetails":[{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":"Acute Aluminum Phosphide Poisoned Cases","enrollment":74},{"nctId":"NCT00965406","phase":"PHASE3","title":"Glucose Insulin Potassium With Intensive Insulin Therapy and (GIK2) Versus GIK Alone","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2010-08","conditions":"Acute Coronary Syndrome","enrollment":772}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GIKI2"],"phase":"phase_3","status":"active","brandName":"GIK and intensive insulin therapy","genericName":"GIK and intensive insulin therapy","companyName":"University of Monastir","companyId":"university-of-monastir","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GIK (glucose-insulin-potassium) therapy combined with intensive insulin regimens improves myocardial metabolism and reduces ischemic injury by enhancing glucose uptake and oxidative metabolism in cardiac tissue. Used for Acute myocardial infarction with intensive glycemic control.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}